Compare BORR & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BORR | EYPT |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Laboratory Analytical Instruments |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2017 | 2005 |
| Metric | BORR | EYPT |
|---|---|---|
| Price | $4.46 | $5.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.25 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 5.7M | 5.6M |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $5.80 | N/A |
| Revenue Next Year | $21.67 | $3,115.57 |
| P/E Ratio | $20.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.45 | $3.95 |
| 52 Week High | $6.66 | $19.11 |
| Indicator | BORR | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 56.99 | 30.17 |
| Support Level | $3.74 | $3.95 |
| Resistance Level | $4.51 | $15.17 |
| Average True Range (ATR) | 0.21 | 0.81 |
| MACD | 0.05 | -0.75 |
| Stochastic Oscillator | 80.52 | 10.83 |
Borr Drilling Ltd is an offshore shallow-water drilling contractor providing services to the oil and gas industry. Its operations focus on the ownership, contracting, and operation of jack-up rigs in shallow-water areas, including the provision of related equipment and work crews to conduct oil and gas drilling and workover operations for exploration and production (E&P) customers. The company contracts its rigs on a dayrate basis to drill wells for integrated oil companies, state-owned national oil companies, and independent oil and gas companies. It operates in one reportable segment.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.